Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance

Jonathan Douxfils; Charlotte Beaudart; Jean-Michel Dogné

doi:10.1080/14656566.2024.2410398

Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance

Jonathan Douxfils, Charlotte Beaudart, Jean-Michel Dogné

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1971-1972
Number of pages	2
Journal	Expert Opinion on Pharmacotherapy
Volume	25
Issue number	14
DOIs	https://doi.org/10.1080/14656566.2024.2410398
Publication status	Published - 2024

Keywords

elinzanetant
Fezolinetant
neoplasm
neurokinin 3 receptor antagonists
public health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14656566.2024.2410398

Cite this

@article{0624948e8ff3431381438346847a7de1,

title = "Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance",

keywords = "elinzanetant, Fezolinetant, neoplasm, neurokinin 3 receptor antagonists, public health",

author = "Jonathan Douxfils and Charlotte Beaudart and Jean-Michel Dogn{\'e}",

year = "2024",

doi = "10.1080/14656566.2024.2410398",

language = "English",

volume = "25",

pages = "1971--1972",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor & Francis",

number = "14",

}

TY - JOUR

T1 - Fezolinetant

T2 - a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance

AU - Douxfils, Jonathan

AU - Beaudart, Charlotte

AU - Dogné, Jean-Michel

PY - 2024

Y1 - 2024

KW - elinzanetant

KW - Fezolinetant

KW - neoplasm

KW - neurokinin 3 receptor antagonists

KW - public health

UR - http://www.scopus.com/inward/record.url?scp=85205509663&partnerID=8YFLogxK

U2 - 10.1080/14656566.2024.2410398

DO - 10.1080/14656566.2024.2410398

M3 - Letter

C2 - 39323314

AN - SCOPUS:85205509663

SN - 1465-6566

VL - 25

SP - 1971

EP - 1972

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 14

ER -

Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance

Keywords

UN SDGs

Access to Document

Other files and links

Clinical Pharmacology Research Group

Cite this

Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance

Keywords

UN SDGs

Access to Document

Other files and links

Projects

Clinical Pharmacology Research Group

Cite this